[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"St. Anne's University Hospital Brno, Czech Republic\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":292},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,45,76,99,124,154,185,220,240,264],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100640065","tracp-5b-for-diagnosis-and-follow-up-of-giant-cell-tumor-of-bone-100640065",false,"NCT07609277","TRACP-5b for Diagnosis and Follow-up of Giant Cell Tumor of Bone","TRACP-5b as a Novel Biomarker for the Diagnosis and Monitoring of Patients With Giant Cell Tumor of Bone","Inclusion Criteria:\n\n* Histologically confirmed Giant Cell Tumor of Bone\n* Newly diagnosed patients or patients undergoing long-term follow-up after previous treatment\n* Age ≥18 years\n* Ability to understand the study procedures and provide written informed consent\n\nExclusion Criteria:\n\n* Concurrent diseases significantly affecting bone metabolism, including metabolic bone disorders\n* Inability or unwillingness to provide informed consent\n* Patients unable to comply with routine follow-up procedures\n* Active conditions that may substantially influence serum TRACP-5b levels independently of Giant Cell Tumor of Bone evaluation","ALL","18 Years",{"count":19,"type":20},70,"ESTIMATED","24 Months","OBSERVATIONAL","This prospective observational study will evaluate whether the blood biomarker TRACP-5b can help diagnose and monitor patients with giant cell tumor of bone (GCTB). GCTB is a rare but locally aggressive bone tumor that can return even after surgical treatment. Currently, patients require long-term follow-up based mainly on imaging examinations such as CT or MRI, and suspected recurrence often requires invasive biopsy procedures.\n\nTRACP-5b is an enzyme associated with osteoclast activity that can be measured from a blood sample. Previous studies suggest that TRACP-5b levels may reflect disease activity and risk of recurrence in patients with GCTB. In this study, patients with newly diagnosed GCTB and patients already undergoing long-term follow-up after treatment will undergo regular blood sampling for TRACP-5b measurement during routine outpatient visits. Laboratory results will be compared with the patient's clinical condition, imaging findings, and histological results when available.\n\nThe goal of the study is to determine whether TRACP-5b could become a reliable and minimally invasive tool for earlier detection of disease recurrence and improved long-term monitoring of patients with giant cell tumor of bone.",[25,26,27,28],"Giant Cell Tumor of Bone","TRACP-5b","Disease Surveillance and Monitoring","Tartrate-Resistant Acid Phosphatase 5b",[25,28,30,31],"Bone Tumor Biomarker","Serum Biomarkers","RECRUITING","2026-05-19",{"date":35,"type":36},"2026-05-27","ACTUAL",{"date":38,"type":36},"2026-01-01",{"date":40,"type":20},"2028-05-31",{"name":42,"class":43},"St. Anne's University Hospital Brno, Czech Republic","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":44},"100638252","preoperative-immunonutrition-in-patients-with-bone-and-soft-tissue-sarcomas-100638252","NCT07609329","Preoperative Immunonutrition in Patients With Bone and Soft Tissue Sarcomas","Effect of Preoperative Immunomodulatory Nutritional Intervention on Postoperative Complications and Sarcopenia in Patients With Bone and Soft Tissue Sarcomas","Inclusion Criteria:\n\n* Participants must meet all of the following criteria:\n* Adult patients aged 18 years or older.\n* Histologically confirmed bone sarcoma or soft tissue sarcoma.\n* Localized or oligometastatic disease.\n* Indicated for planned orthopedic tumor resection.\n* Preoperative interval allowing administration of the nutritional intervention for at least 7 days, with 14 days preferred when clinically feasible.\n* Ability to receive oral nutritional supplementation.\n* Signed informed consent for participation in the study.\n\nExclusion Criteria:\n\n* Participants will be excluded if any of the following criteria are present:\n* Indication for urgent surgery.\n* Disseminated disease with more than five metastases.\n* Ongoing parenteral nutrition before study enrollment.\n* Inability to receive oral intake.\n* Severe hepatic failure.\n* Severe renal failure.",{"count":53,"type":20},100,"INTERVENTIONAL",[56],"NA","This study will evaluate whether a short nutritional intervention before surgery can improve recovery in patients with bone and soft tissue sarcomas.\n\nPatients with these tumors often have a higher risk of poor nutrition and loss of muscle mass. These problems may increase the risk of complications after major orthopedic surgery.\n\nParticipants will be randomly assigned to one of two groups. One group will receive a special oral nutritional supplement twice daily before surgery, in addition to standard care. The other group will receive standard care without the preoperative nutritional supplement.\n\nThe main aim of the study is to compare the rate of clinically relevant postoperative complications within 30 days after surgery. The study will also evaluate changes in muscle mass on CT scans, blood markers of nutrition and inflammation, nutritional risk, functional status, length of hospital stay, and tolerance of the nutritional supplement.",[59,60,61,62,63],"Bone Sarcoma","Soft Tissue Sarcoma","Sarcopenia","Malnutrition","Postoperative Complications",[65,66,67,62,68,69,61],"Sarcoma","Bone sarcoma","Soft tissue sarcoma","Preoperative Nutrition","Immunonutrition",{"date":35,"type":36},{"date":72,"type":36},"2026-04-01",{"date":74,"type":20},"2028-12-31",{"name":42,"class":43},{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":44},"100410901","osa-as-a-remote-ischemic-preconditioning-in-vascular-surgery-100410901","NCT04630535","OSA as a Remote Ischemic Preconditioning in Vascular Surgery","Obstructive Sleep Apnea as a Remote Ischemic Preconditioning in Patients Scheduled for Aorto-bifemoral Bypass Surgery","Inclusion Criteria:\n\n* patients scheduled for elective aorto-bifemoral bypass (AAA and Leriche syndrome patients)\n\nExclusion Criteria:\n\n* emergent surgery\n* aorto-bifemoral bypass using deep vein graft\n* re-operations\n* known OSA with CPAP treatment",{"count":53,"type":20},"Ischemia and reperfusion (I\u002FR) injury during abdominal aortic aneurysm (AAA) repair is inevitable and may lead to postoperative multi-organ failure. Remote ischemic preconditioning (short periods of ischemia in anticipation of longer period of ischemia) may act protectively against ischemia.\n\nStudies of ischemic preconditioning in patients with AAA are conflicting. Obstructive sleep apnea (OSA) is a sleep disordered breathing syndrome which may have a protective effect against ischemia.\n\nThe investigators hypothesize that I\u002FR injury will be less pronounced in patients who have OSA and that the extent of I\u002FR injury will inversely correlate with OSA severity. Accordingly, the aim of this study is to compare postoperative complications and markers of I\u002FR in patients undergoing elective AAA repair who do and do not have OSA.",[86,87,88],"Obstructive Sleep Apnea","Vascular Aneurysm","Ischemia Reperfusion Injury",[90],"remote preconditioning","2026-04-22",{"date":93,"type":36},"2026-04-27",{"date":95,"type":36},"2020-11-01",{"date":97,"type":20},"2029-01-31",{"name":42,"class":43},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":54,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":44},"100635145","quantitative-analysis-of-cardiac-muscle-perfusion-100635145","NCT07548879","Quantitative Analysis of Cardiac Muscle Perfusion","KAPSS","Inclusion Criteria:\n\n* Signed informed consent\n* Patients indicated for a non-invasive test for ischemic heart disease\u002Fchronic coronary syndrome\n* Patients with intermittent chest pain and low to moderate probability of chronic coronary syndrome\n\nExclusion Criteria:\n\n* Presence of relative or absolute contraindications to stress testing, including acute coronary syndrome, life-threatening arrhythmias, severe chronic obstructive pulmonary disease (COPD), or second- or third-degree atrioventricular (AV) block.\n* Contraindications to MRI, such as severe claustrophobia, presence of ferromagnetic material or implants, or severe renal impairment.",{"count":107,"type":20},35,[56],"Full quantitative perfusion of the myocardial wall using MRI is a difficult method for several reasons. First the perfusion algorithm is mostly only relatively available, usually available algorithms \u002Fe.g. ISP\u002F shows not precise results according to our measurements, secondly based on signal physics and nature of MRI scans is not easy to get absolute numbers and specific new algorithms must be developed and tested. Such a tool is not only needed for some special cohort of patients, like 3-vessel disease, coronary artery disease or diffuse coronary artery involvement in coronary vasculopathy in patients after heart transplantation. Fully quantitative perfusion analysis is highly needed for nearly all cardiac patients to better characterise the health and status of the myocardium.",[111],"Myocardial Ischemia",[113,114],"Fully quantitative stress perfusion","CMR","NOT_YET_RECRUITING","2026-04-16",{"date":118,"type":36},"2026-04-23",{"date":120,"type":20},"2026-06-01",{"date":122,"type":20},"2029-12-30",{"name":42,"class":43},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":54,"phases":134,"briefSummary":135,"conditions":136,"keywords":140,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":151,"leadSponsor":153,"locationsCount":44},"100628847","minimally-invasive-non-surgical-therapy-of-peri-implantitis-100628847","NCT07466966","Minimally-Invasive Non-Surgical Therapy of Peri-Implantitis","Minimally-Invasive Non-Surgical Therapy of Peri-Implantitis: A Multicenter Randomized Controlled Trial (MINST vs NSPT)","MINST vs NSPT","Inclusion Criteria:\n\n* Age ≥18\n* Peri-implantitis diagnosis (PPD \\>6 mm, BOP+, bone loss ≥3 mm)\n* Accessible implant surface without removing suprastructure\n* FMPS \\\u003C30%, FMBS \\\u003C30-35%\n\nExclusion Criteria:\n\n* Antibiotics in last 3 months\n* Pregnancy\u002Flactation\n* Uncontrolled diabetes (HbA1c ≥7)\n* Long-term SPIC (\\>2 years)\n* Previous implant therapy \\\u003C12 months\n* Smoking\u002Fvaping in last 12 months\n* Hopeless implant\n* Need for adjunctive antibiotics",{"count":133,"type":20},106,[56],"This multicenter, single-masked randomized controlled clinical trial evaluates the effectiveness of minimally-invasive non-surgical therapy (MINST) compared with standard non-surgical peri-implant therapy (NSPT) in patients diagnosed with peri-implantitis. The study investigates clinical outcomes, radiographic bone levels, patient-reported outcomes, and treatment time over 12 months.",[137,138,139],"Peri-implantitis","Periodontitis","Non-surgical Periodontal Therapy",[141,142,143,144,145,146],"peri-implantitis","MINST","non-surgical therapy","ultrasonic debridement","implant dentistry","randomised controlled trial","2026-03-11",{"date":149,"type":36},"2026-03-13",{"date":38,"type":36},{"date":152,"type":20},"2028-04",{"name":42,"class":43},{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":161,"targetDuration":163,"studyType":22,"phases":4,"briefSummary":164,"conditions":165,"keywords":168,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":184,"locationsCount":44},"100617201","diagnostic-and-therapeutic-targets-in-cartilaginous-tumours-100617201","NCT07315542","Diagnostic and Therapeutic Targets in Cartilaginous Tumours","Finding New Diagnostic and Therapeutic Targets in Cartilaginous Tumours","Inclusion Criteria\n\n* Histologically confirmed cartilaginous (chondroid) tumour\n* Diagnosis includes one of the following entities (as available and eligible):\n* Enchondroma\n* Atypical cartilaginous tumour \u002F Grade 1 chondrosarcoma (ACT\u002FG1)\n* Conventional chondrosarcoma (Grade 2-3)\n* Dedifferentiated chondrosarcoma\n* Other rare chondrosarcoma variants (e.g., mesenchymal, clear-cell), if present in the cohort\n* Patients treated and\u002For followed at the First Department of Orthopaedic Surgery, St. Anne's University Hospital Brno\n\nExclusion Criteria\n\n* Insufficient, degraded, or otherwise unusable tissue samples",{"count":162,"type":20},300,"5 Years","This study, \"Finding new diagnostic and therapeutic targets in cartilaginous tumours,\" focuses on improving the diagnosis, prognostic stratification, and treatment options for chondroid tumours, particularly chondrosarcoma. Chondrosarcoma is the most common primary malignant bone tumour in adults and is characterized by resistance to chemotherapy and radiotherapy, making accurate diagnosis and optimal surgical management critical. Distinguishing benign cartilage tumours (enchondromas, atypical cartilaginous tumours) from low-grade chondrosarcoma, and differentiating chondrosarcoma from chondroblastic osteosarcoma, remain major diagnostic challenges.\n\nThe project investigates two key molecular markers: mutations in IDH1\u002F2 genes and non-coding microRNAs (miRNAs). IDH1\u002F2 mutations are frequent in central chondrosarcomas and rare in other mesenchymal tumours, making them promising diagnostic markers. Their presence may also have prognostic significance and therapeutic relevance, as IDH inhibitors are already available for other malignancies. In parallel, deregulated miRNA expression has been implicated in chondrosarcoma biology, influencing tumour growth, invasion, angiogenesis, metastasis, and chemosensitivity. Preliminary data identified distinct miRNA signatures in chondrosarcoma compared with healthy cartilage, including previously unreported miRNAs.\n\nThe study is structured into exploratory and validation phases. Global miRNA expression profiling and IDH1\u002F2 mutation analysis will be performed using next-generation sequencing (NGS) on prospectively collected fresh-frozen tumour samples. Selected miRNAs and IDH1\u002F2 mutation status will then be validated by RT-qPCR and targeted mutation assays in a large retrospective cohort of FFPE samples. Molecular data will be integrated with clinicopathological parameters to develop diagnostic panels capable of accurately classifying chondroid tumours, as well as prognostic miRNA panels associated with patient survival.\n\nAdditionally, the project evaluates circulating and exosomal miRNAs in liquid biopsies, aiming to establish non-invasive diagnostic and prognostic tools. Functional relevance will be explored using chondrosarcoma cell lines with simulated miRNA upregulation, coupled with transcriptomic analysis.\n\nOverall, the study seeks to refine diagnostic accuracy, improve prognostic assessment, and identify novel molecular targets for personalized and targeted therapy in patients with inoperable or metastatic chondrosarcoma, addressing a major unmet clinical need.",[166,167],"Chondrosarcomas","Cartilage Tumours",[169,170,171,172,173,174,175,176,177],"Chondrosarcoma","Liquid biopsy","Targeted therapy","Prognostic markers","Molecular biomarkers","MicroRNA (miRNA)","Cartilaginous tumours","IDH1 mutation","IDH2 mutation","2026-01-02",{"date":180,"type":36},"2026-01-05",{"date":182,"type":36},"2025-05-01",{"date":74,"type":20},{"name":42,"class":43},{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":54,"phases":196,"briefSummary":197,"conditions":198,"keywords":206,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":44},"100596179","lifestyle-for-the-brain-health---time-restricted-eating-and-mindfulness-100596179","NCT07042087","Lifestyle for the BRAin Health - Time Restricted Eating and Mindfulness","LIBRA REMIND","Inclusion Criteria:\n\n* Age 60-80 years\n* Diagnosis of Subjective Cognitive Impairment (SCI) or Mild Cognitive Impairment (MCI)\n* mini-mental-scale (MMSE) score between 24-30\n* Positive plasma pTau217 biomarker\n* Stable dose of iAChE therapy (if applicable)\n* Ability to participate in a 9-month intervention\n\nExclusion Criteria:\n\n* Stroke or myocardial infarction within the past year\n* Decompensated internal conditions (e.g., severe heart failure, kidney failure, unstable diabetes, GLP1 agonist therapy)\n* Long-term psychiatric treatment (except well-managed depression)\n* Neurological conditions affecting mobility or cognition (e.g., Parkinson's disease, severe tremor, epilepsy)\n* Severe sensory or motor impairment preventing protocol participation\n* Active cancer treated within the past 5 years\n* Poor anticipated compliance (e.g., transport issues, time constraints, non-cooperation)\n* Concurrent participation in another clinical study\n* Unstable iAChE medication regimen\n* Substance or alcohol dependence","60 Years","80 Years",{"count":195,"type":20},48,[56],"The study aims to evaluate the effects of a 9-month intervention combining yoga-based mindfulness techniques, cognitive training, and nutritional counseling on cognitive function, plasma markers of neurodegeneration (tau protein), physical fitness, and metabolism in older adults at increased risk of developing Alzheimer's disease.",[199,200,201,202,203,204,205],"Alzheimer Disease","Aging","Lifestyle Factors","Cognitive Impairment","Yoga","Time Restricted Eating","Diet Modification",[207,208,209,210,211],"Alzheimer's Disease Prevention","Mindfulness-Based Intervention","Cognitive Training","Time-Restricted Eating","Dietary consultation","2025-06-19",{"date":214,"type":36},"2025-06-27",{"date":216,"type":36},"2024-11-01",{"date":218,"type":20},"2026-12",{"name":42,"class":43},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":237,"leadSponsor":239,"locationsCount":44},"100592115","the-effect-of-perioperative-nutritional-care-on-recovery-after-knee-and-hip-replacement-surgery-100592115","NCT06989229","The Effect of Perioperative Nutritional Care on Recovery After Knee and Hip Replacement Surgery","Prospective Study on the Impact of Perioperative Nutritional Care in Patients Undergoing Total Knee and Hip Arthroplasty on Postoperative Outcomes","Inclusion Criteria:\n\nElective total hip replacement Elective total knee replacement\n\nExclusion Criteria:\n\nHip fracture Diabetes mellitus 1 Insulinotherapy",{"count":228,"type":20},1000,"This prospective observational study will assess the impact of standardized perioperative nutritional care on postoperative outcomes in patients undergoing elective total hip (THA) or knee arthroplasty (TKA) at the First Department of Orthopaedic Surgery, St. Anne's University Hospital in Brno. The protocol includes preoperative patient education, nutritional risk screening, and carbohydrate loading up to two hours before anesthesia, followed by early postoperative refeeding.\n\nData collection will include demographic and surgical variables, nutritional status, carbohydrate intake, and the occurrence of intra- and postoperative complications, including infection and delayed wound healing.\n\nAs perioperative nutritional care is part of routine clinical practice, the study requires no additional interventions or resources. Results will provide evidence on the effectiveness of structured nutritional support in enhancing recovery and reducing complications after joint replacement surgery.",[231,63,232],"Postoperative Outcomes","Length of Hospital Stay","2025-05-21",{"date":235,"type":36},"2025-05-25",{"date":182,"type":36},{"date":238,"type":20},"2027-12-31",{"name":42,"class":43},{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":247,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":263},"100570039","cardiopulmonary-exercise-testing-in-cardiosurgery-patients-100570039","NCT06702059","Cardiopulmonary Exercise Testing in Cardiosurgery Patients","Cardiopulmonary Exercise Testing in the Prediction of Post-operative Complications in Patients Undergoing Coronary Artery Bypass Graft Surgery","Inclusion Criteria:\n\n* patients scheduled for coronary artery bypass graft surgery\n\nExclusion Criteria:\n\n* not able to perform cardiopulmonary exercise testing, off-pump revascularization, without full sternotomy, previous cardiac surgery",{"count":248,"type":20},130,"Cardiopulmonary exercise testing (CPET) is considered to be a gold standard in pre-operative risk assessment and stratification of high risk patients scheduled for major surgery. Surprisingly, only a limited number of studies examined the prognostic role of CPET in cardiothoracic surgery. This is in contrast with rather poor discriminating quality of cardiovascular surgery risk scores and predominantly elderly cardiovascular surgery patients, with significant comorbidity and high degree of frailty. Recently, CPET was shown feasible in coronary artery bypass grafting surgery candidates. Additionally, the rest parameter, which is the partial pressure of end-tidal carbon dioxide (PETCO2) and a submaximal exercise parameter (the VE\u002FVCO2 slope) with good prognostic utility across multiple respiratory exchange ratio values), has been shown to predict mortality and post-operative complications.\n\nWhether these rest and submaximal exercise parameters can be used to predict postoperative complications in cardiovascular surgery patients is yet to be determined.",[63],[252,253,254],"cardiovascular surgery","cardiopulmonary exercise testing","post-operative complications","2025-05-12",{"date":257,"type":36},"2025-05-15",{"date":259,"type":36},"2024-12-01",{"date":261,"type":20},"2028-04-01",{"name":42,"class":43},2,{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":269,"acronym":270,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":272,"enrollmentInfo":273,"targetDuration":4,"studyType":54,"phases":275,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":115,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":44},"100560601","phase-2-evaluation-of-the-safety-and-efficacy-of-parecoxib-in-patients-with-subarachnoid-hemorrhage-100560601","NCT06579274","Evaluation of the Safety and Efficacy of Parecoxib in Patients With Subarachnoid Hemorrhage","A Randomized, Placebo-controlled, Double-blind Clinical Trial Evaluating the Safety and Efficacy of Parecoxib in Hospitalized Patients With Spontaneous Subarachnoid Hemorrhage","PARISAH","Inclusion Criteria:\n\n* Signed informed consent\n* Age: 18-85 years\n* Weight\\> 50 kg\n* Spontaneous SAH diagnosed on a native CT brain max. 48 hours after the first symptoms\n* Spontaneous SAH caused by rupture of the cerebral aneurysm confirmed on DSA or CT angiography (Fisher grade 1 to 4) OR Spontaneous SAH without a source on CT AG, DSA or MRI with Fisher grade 3 and 4\n* For women capable of becoming pregnant (see definitions from the CTFG guideline for contraception): use of the following highly reliable contraceptive method within 3 months after the end of the study: adherence to sexual abstinence or contraception containing progesterone with inhibition of ovulation (oral administration, injection) or non-hormonal intrauterine device or hormonal or bilateral tubal occlusion or partner vasectomy. Males: adherence to sexual abstinence or use of an adequate contraceptive method (i.e. condom) in case of sexual intercourse within 3 months after the end of the study.\n\nExclusion Criteria:\n\n* Symptoms of SAH without the finding of blood on the initial native CT scan of the brain\n* SAH from a cause other than a ruptured aneurysm, e.g. A-V malformation, traumatic SAH\n* Pregnancy and breastfeeding (pregnancy test)\n* Known hypersensitivity to the components of the product\n* Allergic reaction to the active substance or sulfonamides in the anamnesis\n* Concomitant treatment with other non-steroidal anti-inflammatory drugs, aspirin or corticosteroids (at least five half-lives before administration of the medicinal product under investigation)\n* Severe hepatic insufficiency (serum albumin level \\\u003C25 g\u002Fl or Child-Pugh score less than 10).\n* Active peptic ulcer or bleeding from the gastrointestinal tract in the anamnesis\n* Inflammatory bowel disease in the anamnesis\n* Congestive heart failure (NYHA II-IV) in history.\n* Proven ischemic heart disease, peripheral arterial insufficiency.\n* Participation in another clinical study (a gap of at least five half-lives before administration of the medicinal product under investigation).","85 Years",{"count":274,"type":20},112,[276],"PHASE2","Because of the important role of inflammation in the pathophysiology of SAH, it was hypothesized that its pharmacological manipulation might improve the prognosis of patients. In recent years, the effects of several groups of anti-inflammatory drugs on the development of complications after SAH have been described. Initially promising, glucocorticoids, thought to reduce cerebrovascular inflammation, brain swelling, and headache, failed in clinical trials. Studies have not provided clear evidence of the beneficial effects of these drugs in patients after SAH. Therefore, the administration of glucocorticoids is not currently part of the recommended practice. In addition, glucocorticoid treatment is associated with adverse effects that worsen outcomes, including hyperglycemia, infection, and the risk of gastrointestinal bleeding.",[279],"Neurological Complication",[281,282,283],"subarachnoidal hemorrhage","inflammation","NSAIDs","2024-08-26",{"date":286,"type":36},"2024-08-30",{"date":288,"type":20},"2025-01-01",{"date":290,"type":20},"2027-07-01",{"name":42,"class":43},""]